Adult w/ chronic phase, accelerated phase or blast phase chronic myeloid leukaemia (CML) resistant to dasatinib or nilotinib; patients intolerant to dasatinib or nilotinib & for subsequent treatment w/ imatinib that is not clinically appropriate; or patients w/ T315I mutation; Philadelphia chromosome +ve acute lymphoblastic leukaemia (Ph+ ALL) that is resistant to dasatinib; patients intolerant to dasatinib & for subsequent treatment w/ imatinib that is not clinically appropriate; or patients w/ T315I mutation.
Myelosuppression; arterial occlusions, including fatal MI, stroke, retinal arterial occlusions associated w/ permanent visual impairment or vision loss, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, renal artery stenosis (associated w/ worsening, labile or treatment-resistant HTN) & the need for urgent revascularization procedures; venous thromboembolism; HTN; aneurysm & artery dissections; CHF; pancreatitis; hepatoxicity; haemorrhage; hepatitis B reactivation; posterior reversible encephalopathy syndrome; risk of bleeding w/ anti-clotting agents; QT prolongation; galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Hepatic or renal impairment. May affect ability to drive or operate machines. Women of child breading potential/contraception in male/female. Pregnancy & lactation. Childn.
Sign Out
